PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Combination of Immune Checkpoint Inhibitors PD-1 Monoclonal Antibody and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Retrospective Cohort Study

This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical carcinomas. Patients may or may not accept PD-1 antibody as maintenance therapy. Patients are followed up and the survival outcomes are evaluated. The primary endpoint are objective remission rate. The secondary endpoints are progression-free survival, overall survival and severe adverse events.

Inclusion Criteria:

• Aged 18 years or older
• Confirmed of recurrent, metastatic, and persistent advanced cervical cancer
• Confirmed of subtypes of cervical squamous carcinoma, adenocarcinoma and adenosquamous carcinoma
• Accepting radiotherapy with concurrent anti PD-1 therapy
• With detailed follow-up outcomes

Exclusion Criteria:

- Not meeting all of the inclusion criteria